Familial amyloidosis diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Xyz}}
{{Familial amyloidosis}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}{{Fs}}
== Overview ==
== Overview ==
[[Biopsy|Tissue biopsy]] with [[Congo red|Congo red stain]] is the [[Gold standard (test)|gold standard test]] for the [[diagnosis]] of [[amyloidosis]]. [[Biopsy]] may be taken from an affected [[Organ (anatomy)|organ]] such as [[kidney]], or from [[subcutaneous fat]] or [[rectal]] [[Mucous membrane|mucosa]]. There are no established criteria for the [[diagnosis]] of familial amyloidosis.


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==
Line 8: Line 9:
=== Study of choice ===
=== Study of choice ===


* Tissue biopsy with Congo red stain is the gold standard test for the diagnosis of familial amyloidosis.<ref name="pmid12553428">{{cite journal |vauthors=Benson MD, Yazaki M, Magy N |title=Laboratory assessment of transthyretin amyloidosis |journal=Clin. Chem. Lab. Med. |volume=40 |issue=12 |pages=1262–5 |date=December 2002 |pmid=12553428 |doi=10.1515/CCLM.2002.218 |url=}}</ref>
*[[Biopsy|Tissue biopsy]] with [[Congo red|Congo red stain]] is the [[Gold standard (test)|gold standard test]] for the [[diagnosis]] of [[amyloidosis]].<ref name="pmid12553428">{{cite journal |vauthors=Benson MD, Yazaki M, Magy N |title=Laboratory assessment of transthyretin amyloidosis |journal=Clin. Chem. Lab. Med. |volume=40 |issue=12 |pages=1262–5 |date=December 2002 |pmid=12553428 |doi=10.1515/CCLM.2002.218 |url=}}</ref>


* Biopsy tissue may be taken from an affected organ like kidney, or from subcutaneous fat or rectal mucosa.
*[[Biopsy]] may be taken from an affected [[Organ (anatomy)|organ]] such as [[kidney]], or from [[subcutaneous fat]] or [[rectal]] [[Mucous membrane|mucosa]].
* The rectal mucosa biopsy is more sensitive for:
* The [[rectal]] [[mucosa]] [[biopsy]] is especially [[Sensitivity (tests)|sensitive]] for:
** [[Transthyretin|Transthyretin (TTR)]]
**[[Transthyretin|Transthyretin (TTR)]]
** [[Apolipoprotein AI]]
** [[Apolipoprotein AI]]
** Apolipoprotein AII
** Apolipoprotein AII
** [[Fibrinogen A alpha-chain associated amyloidosis|Fibrinogen Aa]]
** [[Fibrinogen A alpha-chain associated amyloidosis|Fibrinogen Aa]]
* Biopsy of the affected organ is recommended for patients with limited organ involvement.<ref name="pmid12479513">{{cite journal |vauthors=Andrews TR, Colon-Otero G, Calamia KT, Menke DM, Boylan KB, Kyle RA |title=Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy |journal=Mayo Clin. Proc. |volume=77 |issue=12 |pages=1287–90 |date=December 2002 |pmid=12479513 |doi=10.4065/77.12.1287 |url=}}</ref>
*[[Biopsy]] of the affected [[Organ (anatomy)|organ]] is recommended for [[Patient|patients]] with limited [[Organ (anatomy)|organ]] involvement.<ref name="pmid12479513">{{cite journal |vauthors=Andrews TR, Colon-Otero G, Calamia KT, Menke DM, Boylan KB, Kyle RA |title=Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy |journal=Mayo Clin. Proc. |volume=77 |issue=12 |pages=1287–90 |date=December 2002 |pmid=12479513 |doi=10.4065/77.12.1287 |url=}}</ref>
* Biopsy from unaffected organs is more sensitive in patients with multi-organ involvement.
*[[Biopsy]] from unaffected [[Organ (anatomy)|organs]] is more [[Sensitivity (tests)|sensitive]] in [[Patient|patients]] with multi-organ involvement.


===== Diagnostic results =====
===== Diagnostic Results =====
The following finding on performing tissue biopsy is confirmatory for familial amyloidosis:<ref name="pmid13657054">{{cite journal |vauthors=COHEN AS, CALKINS E |title=Electron microscopic observations on a fibrous component in amyloid of diverse origins |journal=Nature |volume=183 |issue=4669 |pages=1202–3 |date=April 1959 |pmid=13657054 |doi=10.1038/1831202a0 |url=}}</ref><ref name="pmid11552976">{{cite journal |vauthors=Kyle RA |title=Amyloidosis: a convoluted story |journal=Br. J. Haematol. |volume=114 |issue=3 |pages=529–38 |date=September 2001 |pmid=11552976 |doi=10.1046/j.1365-2141.2001.02999.x |url=}}</ref>
The following finding on [[Biopsy|tissue biopsy]] is confirmatory for familial amyloidosis:<ref name="pmid13657054">{{cite journal |vauthors=COHEN AS, CALKINS E |title=Electron microscopic observations on a fibrous component in amyloid of diverse origins |journal=Nature |volume=183 |issue=4669 |pages=1202–3 |date=April 1959 |pmid=13657054 |doi=10.1038/1831202a0 |url=}}</ref><ref name="pmid11552976">{{cite journal |vauthors=Kyle RA |title=Amyloidosis: a convoluted story |journal=Br. J. Haematol. |volume=114 |issue=3 |pages=529–38 |date=September 2001 |pmid=11552976 |doi=10.1046/j.1365-2141.2001.02999.x |url=}}</ref>


* Apple green birefringence of the tissue sample under polarized light with Congo red stain.
* Apple green birefringence of the [[tissue]] sample under polarized light with [[Congo red|Congo red stain]].
*  
*  


===== Sequence of Diagnostic Studies =====
===== Sequence of Diagnostic Studies =====
The [name of investigation] must be performed when:
* The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
* A positive [test] is detected in the patient, to confirm the diagnosis.
OR
The various investigations must be performed in the following order:
The various investigations must be performed in the following order:
* [Initial investigation]
* History
* [2nd investigation]
**Although all the familial amyloidosis types are [[autosomal dominant]], different degree of temperance makes it difficult to [[diagnose]] the [[disease]] based on [[family history]].
*[[Physical examination]]
*[[Biopsy]]


=== Name of Diagnostic Criteria ===
=== Name of Diagnostic Criteria ===
 
There are no established criteria for the [[diagnosis]] of familial amyloidosis.
'''It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.'''
 
[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
 
OR
 
There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].
 
OR
 
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
 
OR
 
The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
 
OR
 
[Disease name] may be diagnosed at any time if one or more of the following criteria are met:
* Criteria 1
* Criteria 2
* Criteria 3
 
OR
 
'''IF there are clear, established diagnostic criteria'''
 
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
 
OR
 
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
 
OR
 
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
 
OR
 
'''IF there are no established diagnostic criteria'''
 
There are no established criteria for the diagnosis of [disease name].


==References==
==References==

Latest revision as of 19:47, 7 February 2020

Familial amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Familial amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Familial amyloidosis diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Familial amyloidosis diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Familial amyloidosis diagnostic study of choice

CDC on Familial amyloidosis diagnostic study of choice

Familial amyloidosis diagnostic study of choice in the news

Blogs on Familial amyloidosis diagnostic study of choice

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Familial amyloidosis diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Tissue biopsy with Congo red stain is the gold standard test for the diagnosis of amyloidosis. Biopsy may be taken from an affected organ such as kidney, or from subcutaneous fat or rectal mucosa. There are no established criteria for the diagnosis of familial amyloidosis.

Diagnostic Study of Choice

Study of choice

Diagnostic Results

The following finding on tissue biopsy is confirmatory for familial amyloidosis:[3][4]

Sequence of Diagnostic Studies

The various investigations must be performed in the following order:

Name of Diagnostic Criteria

There are no established criteria for the diagnosis of familial amyloidosis.

References

  1. Benson MD, Yazaki M, Magy N (December 2002). "Laboratory assessment of transthyretin amyloidosis". Clin. Chem. Lab. Med. 40 (12): 1262–5. doi:10.1515/CCLM.2002.218. PMID 12553428.
  2. Andrews TR, Colon-Otero G, Calamia KT, Menke DM, Boylan KB, Kyle RA (December 2002). "Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy". Mayo Clin. Proc. 77 (12): 1287–90. doi:10.4065/77.12.1287. PMID 12479513.
  3. COHEN AS, CALKINS E (April 1959). "Electron microscopic observations on a fibrous component in amyloid of diverse origins". Nature. 183 (4669): 1202–3. doi:10.1038/1831202a0. PMID 13657054.
  4. Kyle RA (September 2001). "Amyloidosis: a convoluted story". Br. J. Haematol. 114 (3): 529–38. doi:10.1046/j.1365-2141.2001.02999.x. PMID 11552976.

Template:WH Template:WS